CJC-1295 (No DAC) vs IGF-1
CJC-1295 (No DAC) and IGF-1 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: CJC-1295 (No DAC) is ghrh(1-29) tetra-substituted analogue (dac-free), while IGF-1 is 70-residue single-chain protein (native igf-1), three disulfide bonds — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid for initial dissolution); their leading degradation routes differ (deamidation at asn/gln residues over long solution storage. for CJC-1295 (No DAC), misfolding and irreversible denaturation for IGF-1), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 (No DAC) — origin
CJC-1295 without DAC is the first 29 residues of growth-hormone-releasing hormone carrying four stabilising substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-4 cleavage. Omitting the Drug Affinity Complex — the albumin-binding element of the DAC version — gives it a short half-life, which is the property researchers study it for.
IGF-1 — origin
IGF-1 is the native insulin-like growth factor — a folded 70-amino-acid protein stabilised by three internal disulfide bonds. It is the downstream messenger produced after growth hormone acts, and it is handled as a protein rather than a short peptide. This is the native sequence, distinct from the long-acting LR3 analogue.
CJC-1295 (No DAC) research themes
Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.
The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.
Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.
IGF-1 research themes
Studied as the native ligand for the IGF-1 receptor and its downstream proliferation and survival pathways.
Examined in muscle research models for its role in satellite-cell behaviour and anabolic signalling.
Compared with IGF-1 LR3, whose reduced binding-protein affinity gives a longer active window — a contrast studied directly in the literature.
CJC-1295 (No DAC) handling
- Reach room temperature before opening.
- Swirl to dissolve; do not shake or vortex — foam indicates interfacial stress on the helix.
- Aliquot and refrigerate; never re-freeze reconstituted solution.
IGF-1 handling
- Dissolve first in dilute acetic acid, then dilute into the working buffer — never expect plain water to take it up fully.
- Use a carrier protein and low-bind labware to prevent adsorptive loss.
- Aliquot for single use; do not re-freeze reconstituted protein.
Both third-party tested
Every Popular Peptides batch of CJC-1295 (No DAC) and IGF-1 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 (No DAC) reference
Related comparisons
CJC-1295 (No DAC) and IGF-1 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.